Cohance Lifesciences Ltd

  • BSE Code : 543064
  • NSE Symbol : COHANCE
  • ISIN : INE03QK01018
  • Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN

up-arrow 933.10 0.25(0.03%)

Open Price ()

942.00

Prev. Close ()

932.85

Volume (No’s)

68,143

Market Cap ()

35,697.34

Low Price ()

925.00

High Price ()

948.25

 

Corporate Announcement

30-Jul-2025 Cohance Lifesciences Limited - Other General Purpose
29-Jul-2025 Cohance Lifesciences Limited - Change in Director
28-Jul-2025 Cohance Lifesciences Limited - Change in Management
23-Jul-2025 Cohance Lifesciences Limited - Analysts/Institutional Investor Meet/Con. Call Updates
30-Jun-2025 Cohance Lifesciences Limited - Trading Window

Stock Summary

Market Cap(₹Cr.)

35,639.95

P/E (TTM)

131.21

Book value ()

60.86

Div Yield (%)

0

EPS (TTM)

7.1

Face Value ()

1.00

Technical Analysis

Key Level

Resistance 1

943.80

Resistance 2

954.75

Support 1

920.45

Support 2

908.05

Moving Average

30 Days

1,007.76

50 Days

1,006.62

100 Days

1,063.11

200 Days

1,122.57

Peers Group

Company Market Cap (₹in Cr.) P/E (x) P/B(x) EV / EBITDA(x) Dividend Yield(%) EPS
Cohance Lifesciences Ltd 35,639.95 131.21 8.38 465 0 7.1
Sun Pharmaceutical Indust.. 380,702.48 76.43 17.11 7162.05 1.01 20.76
Divis Laboratories Ltd 156,907.86 67.17 10.27 3332 0.51 88
Torrent Pharmaceuticals L.. 120,890.67 60.81 14.42 3583.06 0.17 58.74
Cipla Ltd 119,987.40 23.22 3.63 7057.82 1.08 63.96

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made investment of Returns(%)

in Months Ago

My investment would be worth with a Loss of

Share Holding

CATEGORY NO. OF SHARES PERCENTAGE (%)
Total Foreign 30083280 7.86
Total Institutions 43619228 11.40
Total Govt Holding 37834 0.01
Total Non Promoter Corporate Holding 28366751 7.42
Total Promoters 254078170 66.41
Total Public & others 26381877 6.90
Total 382567140 100
  • Total Foreign
  • Total Institutions
  • Total Govt Holding
  • Total Non Promoter Corporate Holding
  • Total Promoters
  • Total Public & others

Corporate Actions

About Company

Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors. The Company's comprehensive services encompass- Custom Synthesis, Process R&D,
Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations.

Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking variou...

Copyright © 2024 Arihant Capital Markets Ltd. All rights Reserved.

Designed,Developed and Content powered by CMOTS Infotech (ISO 9001:2015 certified)

x
  • QR-CodeNew